List of Anti-Cancer Drugs Aproved By the FDA

17,444 views

Here are some anti-cancer drugs. We list here just the main drugs aproved by the FDA. In the near future we will link the name of
all these drugs to one page explaining more about them.




Drug Drug Trade Name Approved Use Manufacturer/Distributor Approval Date
abarelix Plenaxis depot For the palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following: (1) risk of neurological compromise due to metastases, (2) ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or (3) severe bone pain from skeletal metastases persisting on narcotic analgesia Praecis Nov 25 2003
aldesleukin Prokine Treatment of adults with metastatic melanoma Chiron Jan 09 1998
Aldesleukin Proleukin Treatment of adults with metastatic renal cell carcinoma Chiron Corp May 05 1992
Alemtuzumab Campath Accel. Approv. (clinical benefit not established) Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Millennium and ILEX Partners, LP May 07 2001
alitretinoin Panretin Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Ligand Pharmaceuticals Feb 02 1999
allopurinol Zyloprim Patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. GlaxoSmithKline May 17 1996
altretamine Hexalen Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination. US Bioscience Dec 26 1990
amifostine Ethyol To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer US Bioscience Dec 08 1995
amifostine Ethyol Accel. Approv. (clinical benefit not established) Reduction of platinum toxicity in non-small cell lung cancer US Bioscience Mar 15 1996
amifostine Ethyol To reduce post-radiation xerostomia for head and neck cancer where the radiation port includes a substantial portion of the parotid glands. US Bioscience Jun 24 1999
anakinra Kineret pediatric Use section of the US product label and to fulfill PMC #3 to assess the safety and efficacy of anakinra in pediatric patients with juvenile rheumatoid arthritis Amgen Dec 15 2006
anastrozole Arimidex Accel. Approv. (clinical benefit not established) for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer AstraZeneca Sep 05 2002
anastrozole Arimidex Conversion to regular approval for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer AstraZeneca Sep 16 2005
anastrozole Arimidex Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. AstraZeneca Pharmaceuticals Dec 27 1995
anastrozole Arimidex For first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. AstraZeneca Pharmaceuticals Sep 01 2000
arsenic trioxide Trisenox Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline. Cell Therapeutic Sep 25 2000
asparaginase Elspar Therapy of patients with acute lymphocytic leukemia Merck Jan 10 1978
Asparaginase Elspar ELSPAR is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. Merck & Co, Inc Aug 01 2002
azacitidine Vidaza For use for the treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia Pharmion May 19 2004
azacitidine Vidaza indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Pharmion Jan 26 2007
BCG Live TICE BCG Organon Teknika Corp Aug 21 1998
bevacizumab Avastin Metastatic colon carcinoma Genentech Jun 20 2006
bevacizumab Avastin FDA approved changed in the Avastin package insert regarding warning and dose and administration for Reversible Posterior Leukoencephalopathy Syndrome. Nasal septum perforation was also added as a serious adverse event. Genentech Sep 21 2006
bevacizumab Avastin a first-line treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer in combination with platinum-based chemotherapy Genentech Oct 11 2006
bevacuzimab Avastin First-line treatment of patients with metastatic carcinoma of the colon and rectum (in combination with intravenous 5-fluorouracil-based chemotherapy) Genentech Feb 26 2004
bexarotene capsules Targretin For the treatment by oral capsule of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals Dec 29 1999
bexarotene gel Targretin For the topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals Jun 28 2000
bleomycin Blenoxane Bristol-Myers Squibb Jul 31 1973
bleomycin Blenoxane Sclerosing agent for the treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions. Bristol-Myers Squibb Feb 20 1996
bortezombi Velcade for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy Millennium Dec 08 2006
bortezomib Velcade Accel. Approv. (clinical benefit not established) for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy Millenium May 13 2003
bortezomib Velcade Conversion to regular approval for treatment of multiple myeloma patients who have received as least one prior therapy Millenium Mar 25 2005
busulfan intravenous Busulfex Use in combination with cyclophoshamide as conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Orphan Medical, Inc Feb 04 1999
busulfan oral Myleran Chronic Myelogenous Leukemia- palliative therapy GlaxoSmithKline Jun 26 1954
calusterone Methosarb Pharmacia & Upjohn Company Feb 20 1973
capecitabine Xeloda Accel. Approv. (clinical benefit subsequently established) Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents Roche Apr 30 1998
capecitabine Xeloda Initial therapy of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5_FU/LV has not been demonstrated with Xeloda monotherapy. Roche Apr 30 2001
capecitabine Xeloda Conversion to regular approval for treatment in combination with docetaxel of patients with metastatic breast cancer after failure of prior anthracycline containing chemotherapy Roche Sep 07 2001
capecitabine Xeloda Adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred Roche Jun 15 2005
carboplatin Paraplatin Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Bristol-Myers Squibb Mar 03 1989
carboplatin Paraplatin Initial chemotherapy of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb Jul 05 1991
carmustine BCNU, BiCNU Bristol-Myers Squibb Mar 07 1977
carmustine Gliadel Treatment of patients with malignant glioma undergoing primary surgical resection MGI Pharma Feb 25 2003
carmustine with Polifeprosan 20 Implant Gliadel Wafer For use in addition to surgery to prolong survival in patients with recurrent glioblastoma multiforme who qualify for surgery. Guilford Pharmaceuticals Inc. Sep 23 1996
celecoxib Celebrex Accel. Approv. (clinical benefit not established) Reduction of polyp number in patients with the rare genetic disorder of familial adenomatous polyposis. Searle Dec 23 1999
cetuximab Erbitux Accel. Approv. (clinical benefit not established) for treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy (in combination with irinotecan); as a single agent, treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy Imclone Feb 12 2004
cetuximab Erbitux For use in combination with radiation therapy (RT) for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) or as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed. Imclone Mar 01 2006
chlorambucil Leukeran GlaxoSmithKline Mar 18 1957
cisplatin Platinol Metastatic testicular-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors whoc have already received appropriate surgical and/or radiotherapeutic procedures. An established combination therapy consists of Platinol, Blenoxane and Velbam. Bristol-Myers Squibb Dec 19 1978
cisplatin Platinol Metastatic ovarian tumors - in established combination therapy with other approved chemotherapeutic agents: Ovarian-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Adriamycin. Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Platinol therapy. Bristol-Myers Squibb Dec 19 1978
cisplatin Platinol as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy. Bristol-Myers Squibb Apr 22 1993
cladribine Leustatin, 2-CdA Treatment of active hairy cell leukemia. R.W. Johnson Pharmaceutical Research Institute Feb 26 1993
clofarabine Clolar Accel. Approv. (clinical benefit not established) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens Genzyme Dec 28 2004
cyclophosphamide Cytoxan, Neosar Bristol-Myers Squibb Nov 16 1959
cyclophosphamide Cytoxan Injection Bristol-Myers Squibb Nov 16 1959
cyclophosphamide Cytoxan Injection Bristol-Myers Squibb Apr 29 1987
cyclophosphamide Cytoxan Tablet Bristol-Myers Squibb Apr 29 1987
cytarabine Cytosar-U Pharmacia & Upjohn Company Jun 17 1969
cytarabine liposomal DepoCyt Accel. Approv. (clinical benefit not established) Intrathecal therapy of lymphomatous meningitis Skye Pharmaceuticals Apr 01 1999
dacarbazine DTIC-Dome Bayer May 27 1975
dactinomycin, actinomycin D Cosmegen Merck Feb 04 1964
dactinomycin, actinomycin D Cosmegan Merck Dec 10 1964
dalteparin sodium Fragmin provides for the use of Fragmin (dalteparin sodium injection) for extended treatment of symptomatic venous thromboembolism (VTE) [proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)] to reduce the recurrence of VTE in patients with cancer. Pharmacia & Upjohn May 01 2007
darbepoetin alfa Aranesp for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Amgen Mar 09 2007
darbepoetin alfa Aranesp Amgen Apr 10 2007
Darbepoetin alfa Aranesp Treatment of anemia associated with chronic renal failure. Amgen, Inc Sep 17 2001
Darbepoetin alfa Aranesp Aranesp is indicated for the treatment of anemia in patients with non- myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Amgen, Inc Jul 19 2002
dasatinib Sprycel Chronic myelogenous leukemia Bristol Myers Squibb Jun 28 2006
daunorubicin liposomal DanuoXome First line cytotoxic therapy for advanced, HIV related Kaposi’s sarcoma. Nexstar, Inc. Apr 08 1996
daunorubicin, daunomycin Daunorubicin Leukemia/myelogenous/monocytic/erythroid of adults/remission induction in acute lymphocytic leukemia of children and adults. Bedford Labs Jan 30 1998
daunorubicin, daunomycin Cerubidine In combination with approved anticancer drugs for induction of remission in adult ALL. Wyeth Ayerst Mar 11 1987
decitabine Dacogen for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. MGI PHARMA INC May 05 2006
denileukin Ontak Seragen
Denileukin diftitox Ontak Accel. Approv. (clinical benefit not established) treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor Seragen, Inc Feb 05 1999
dexrazoxane Zinecard Accel. Approv. (clinical benefit subsequently established) Prevention of cardiomyopathy associated with doxorubicin administration Pharmacia & Upjohn Company May 26 1995
dexrazoxane Zinecard Conversion to regular approval for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy. Pharmacia & Upjohn Company Oct 31 2002
docetaxel Taxotere Accel. Approv. (clinical benefit subsequently established) Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy. Aventis Pharmaceutical May 14 1996
docetaxel Taxotere Conversion to regular approval - treatment of locally advanced or metastatic breast cancer which has progressed during anthracycline-based treatment or relapsed during anthracycline-based adjuvant therapy. Aventis Pharmaceutical Jun 22 1998
docetaxel Taxotere For locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Aventis Pharmaceutical Dec 23 1999
docetaxel Taxotere for use in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Aventis Pharmaceutical Nov 27 2002
docetaxel Taxotere For use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer Aventis Pharmaceutical May 19 2004
docetaxel Taxotere For use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable nodepositive breast cancer Aventis Pharmaceutical Aug 18 2004
docetaxel Taxotere for use in combination with cisplatin and fluorouracil for the induction treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck. Sanofi Aventis Oct 17 2006
doxorubicin Adriamycin PFS For use in combination with cyclophosphamide as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer Pharmacia May 08 2003
doxorubicin Adriamycin, Rubex Pharmacia & Upjohn Company Aug 07 1974
doxorubicin Adriamycin PFS Injectionintravenous injection Antibiotic, antitumor agent. Pharmacia & Upjohn Company Dec 23 1987
doxorubicin liposomal Doxil Conversion to regular approval for treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy Alza Jan 28 2005
doxorubicin liposomal Doxil Accel. Approv. (clinical benefit not established) Treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Sequus Pharmaceuticals, Inc. Nov 17 1995
doxorubicin liposomal Doxil Accel. Approv. (clinical benefit not established) Treatment of metastatic carcinoma of the ovary in patient with disease that is refractory to both paclitaxel and platinum based regimens Sequus Pharmaceuticals, Inc. Jun 28 1999
DROMOSTANOLONE PROPIONATE DROMOSTANOLONE Eli Lilly Oct 26 1961
DROMOSTANOLONE PROPIONATE MASTERONE INJECTION SYNTEX Oct 08 1964
eculizumab Soliris for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Alexion Mar 16 2007
Elliott’s B Solution Elliott’s B Solution Diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. Orphan Medical, Inc Sep 27 1996
epirubicin Ellence A component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Pharmacia & Upjohn Company Sep 15 1999
epirubicin hcl epirubicin hcl as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Mayne Sep 15 2006
epoetin alfa Epogen/Procrit is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately. Amgen Mar 09 2007
Epoetin alfa epogen EPOGENB is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. EPOGEND is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. EPOGENB is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately. Amgen, Inc Jul 26 1999
Epoetin alfa epogen EPOGENB is indicated for the reatment of anemia related to therapy with zidovudine in HIV- infected patients. EPOGENB is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEND is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately. Amgen, Inc Jul 26 1999
Epoetin alfa epogen EPOGENB is indicated for the treatment of anemic patients (hemoglobin > 10 to _< 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Amgen, Inc Jul 26 1999
Epoetin alfa epogen EPOGEN is indicated for the treatment of anemia associated with CRF, including patients on dialysis (ESRD) and patients not on dialysis. Amgen, Inch Jul 26 1999
erlotinib Tarceva For treatment of locally advanced or metastatic Non Small-Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen OSI Nov 18 2004
erlotinib Tarceva For use in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer OSI Nov 02 2005
estramustine Emcyt palliation of prostate cancer Pharmacia & Upjohn Company Dec 24 1981
etoposide phosphate Etopophos Management of refractory testicular tumors, in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb May 17 1996
etoposide phosphate Etopophos Management of small cell lung cancer, first-line, in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb May 17 1996
etoposide phosphate Etopophos Management of refractory testicular tumors and small cell lung cancer. Bristol-Myers Squibb Feb 27 1998
etoposide, VP-16 Vepesid Refractory testicular tumors-in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic and radiotherapeutic therapy. Bristol-Myers Squibb Nov 10 1983
etoposide, VP-16 VePesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Myers Squibb Dec 30 1986
etoposide, VP-16 Vepesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Myers Squibb Dec 30 1986
exemestane Aromasin For adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN® for completion of a total of five consecutive years of adjuvant hormonal therapy Pharmacia Oct 05 2005
exemestane Aromasin Treatment of advance breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Pharmacia & Upjohn Company Oct 21 1999
fentanyl citrate Fentora for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Cephalon Sep 25 2006
Filgrastim Neupogen Decrease incidence of infection in patients with nonmyeloid malignancies Amgen, Inc Feb 20 1991
Filgrastim Neupogen NEUPOGEN is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. Amgen, Inc Apr 02 1998
Filgrastim Neupogen NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation hemotherapy treatment of adults with AML. Amgen, Inc Apr 02 1998
Filgrastim Neupogen NEUPOGEN is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. Amgen, Inc Apr 02 1998
floxuridine (intraarterial) FUDR Roche Dec 18 1970
fludarabine Fludara Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen. Berlex Laboratories Inc. Apr 18 1991
fluorouracil, 5-FU Adrucil prolong survival in combination with leucovorin ICN Puerto Rico Apr 25 1962
fulvestrant Faslodex the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy IPR Apr 25 2002
gefitinib Iressa Accel. Approv. (clinical benefit not established ) as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies AstraZenca May 05 2003
gemcitabine Gemzar Treatment of patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. Indicated for first-line treatment and for patients previously treated with a 5-fluorouracil-containing regimen. Eli Lilly May 15 1996
gemcitabine Gemzar For use in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Eli Lilly Aug 25 1998
gemcitabine hcl Gemzar Ovarian cancer Lilly Jul 14 2006
gemicitabine Gemzar For use in combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated Lilly May 19 2004
gemtuzumab ozogamicin Mylotarg Accel. Approv. (clinical benefit not established) Treatment of CD33 positive acute myeloid leukemia in patients in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. Wyeth Ayerst May 17 2000
goserelin acetate Zoladex AstraZeneca Pharmaceuticals Dec 18 1995
goserelin acetate Zoladex Implant Palliative treatment of advanced breast cancer in pre- and perimenopausal women. AstraZeneca Pharmaceuticals Dec 18 1995
histrelin acetate Histrelin implant For the palliative treatment of advanced prostate cancer Valera Oct 12 2004
hydroxyurea Hydrea Bristol-Myers Squibb Dec 07 1967
hydroxyurea Hydrea Decrease need for transfusions in sickle cell anemia Bristol-Myers Squibb Feb 25 1998
Ibritumomab Tiuxetan Zevalin Accel. Approv. (clinical benefit not established) treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma, including patients with Rituximab refractory follicular non-Hodgkin’s lymphoma. IDEC Pharmaceuticals Corp Feb 19 2002
idarubicin Idamycin For use in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults. Adria Laboratories Sep 27 1990
idarubicin Idamycin In combination with other approved antileukemic drugs for the treatment of acute non-lymphocytic leukemia in adults. Pharmacia & Upjohn Company Feb 17 1997
ifosfamide IFEX Third line chemotherapy of germ cell testicular cancer when used in combination with certain other approved antineoplastic agents. Bristol-Myers Squibb Dec 30 1988
imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Initial therapy of chronic myelogenous leukemia Novartis May 10 2001
imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) metastatic or unresectable malignant gastrointestinal stromal tumors Novartis Feb 01 2002
Imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). Novartis Feb 01 2002
imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Initial treatment of newly diagnosed Ph+ chronic myelogenous leukemia (CML). Novartis Dec 20 2002
imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) for treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. Follow-up is limited. Gleevec is also indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival in patients with CML blast crisis, accelerated phase or chronic phase after failure of alpha interferon. Gleevec is also indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) Novartis Apr 18 2003
imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy. Novartis May 20 2003
imatinib mesylate Gleevec Conversion to regular approval for treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy Novartis Dec 08 2003
imatinib mesylate Gleevec for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML). Novartis Sep 27 2006
imatinib mesylate Gleevec single agent for the treatment of multiple indications Novartis Oct 19 2006
interferon alfa 2a Roferon A Treatment of patients with hairy cell leukemia Roche Jun 04 1986
interferon alfa 2a Roferon A Chronic phase, Philadelphia chromosome positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis) Roche Oct 19 1995
Interferon alfa-2a Roferon-A Hoffmann-La Roche Inc Nov 01 1996
Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia. Schering Corp Jun 04 1986
Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas. Schering Corp Jun 06 1988
Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for injection is indicated for the treatment of selected patients 18 years of age or older with AIDS-related Kaposi’s Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count. Schering Corp Nov 21 1988
Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for injection is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence within 56 days of surgery. Schering Corp Dec 05 1995
Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for the initial treatment of clinically aggressive follicular non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Schering Corp Nov 06 1997
Interferon alfa-2b Intron A Intron A Schering Corp Jun 21 2002
irinotecan Camptosar Accel. Approv. (clinical benefit subsequently established) Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company Jun 14 1996
irinotecan Camptosar Conversion to regular approval - treatment of metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company Oct 22 1998
irinotecan Camptosar For first line treatment n combination with 5-FU/leucovorin of metastatic carcinoma of the colon or rectum. Pharmacia & Upjohn Company Apr 20 2000
lapatinib ditosylate Tykerb for use in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. SmithKline Beecham Mar 13 2007
lapatinib ditosylate Tykerb SmithKline Beecham Apr 27 2007
lenalidomide Revlimid Multiple myeloma Celegene Jun 29 2006
lenalidomide Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities Celgene Dec 27 2005
letrozole Femara Treatment of advanced breast cancer in postmenopausal women. Novartis Jul 25 1997
letrozole Femara First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Novartis Jan 10 2001
letrozole Femara Novartis Jan 17 2003
letrozole Femara Accel. Approv. (clinical benefit not established) for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received five years of adjuvant tamoxifen therapy. Novartis Oct 29 2004
leucovorin Wellcovorin, Leucovorin Leucovorin calcium is indicated fro use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Immunex Corporation Jun 20 1952
leucovorin Leucovorin Immunex Corporation Jan 30 1987
leucovorin Leucovorin Immunex Corporation Jan 30 1987
leucovorin Leucovorin Immunex Corporation Aug 31 1988
leucovorin Leucovorin In combination with fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Lederle Laboratories Dec 12 1991
Leuprolide Acetate Eligard palliative treatment of advanced prostate cancer. QLT USA Jan 23 2002
levamisole Ergamisol Adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes’ Stage C colon cancer. Janssen Research Foundation Jun 18 1990
lomustine, CCNU CeeBU Bristol-Myers Squibb Aug 04 1976
meclorethamine, nitrogen mustard Mustargen Merck Mar 15 1949
megestrol acetate Megace Bristol-Myers Squibb Aug 18 1971
melphalan, L-PAM Alkeran GlaxoSmithKline Jan 17 1964
melphalan, L-PAM Alkeran Systemic administration for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. GlaxoSmithKline Nov 18 1992
mercaptopurine, 6-MP Purinethol GlaxoSmithKline Sep 11 1953
mesna Mesnex Prevention of ifosfamide-induced hemorrhagic cystitis Asta Medica Dec 30 1988
mesna Mesnex tabs Reducing the incidence of ifosfamide-induced hemorrhagic cystitis Baxter Mar 21 2002
methotrexate Methotrexate Lederle Laboratories Dec 07 1953
methotrexate Methotrexate Lederle Laboratories Aug 10 1959
methotrexate Methotrexate Lederle Laboratories Nov 01 1971
methotrexate Methotrexate Lederle Laboratories Nov 01 1971
methotrexate Methotrexate osteosarcoma Lederle Laboratories Apr 07 1988
methotrexate Methotrexate Lederle Laboratories Oct 31 1988
methoxsalen Uvadex For the use of UVADEX with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. Therakos Feb 25 1999
mitomycin C Mutamycin Bristol-Myers Squibb May 28 1974
mitomycin C Mitozytrex therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Supergen Nov 14 2002
mitotane Lysodren Bristol-Myers Squibb Jul 08 1970
mitoxantrone Novantrone For use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Immunex Corporation Nov 13 1996
mitoxantrone Novantrone For use with other approved drugs in the initial therapy for acute nonlymphocytic leukemia (ANLL) in adults. Lederle Laboratories Dec 23 1987
nandrolone phenpropionate Durabolin-50 Organon Oct 30 1959
nelarabine Arranon Accel. Approv. (clinical benefit not established) for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens GlaxoSmithKline Oct 28 2005
Nofetumomab Verluma Boehringer Ingelheim Pharma KG (formerly Dr. Karl Thomae GmbH) Aug 20 1996
Oprelvekin Neumega Prevention of severe thrombocytopenia following myelosuppressive chemotherapy Genetics Institute, Inc Nov 25 1997
Oprelvekin Neumega Genetics Institute, Inc Sep 18 2002
Oprelvekin Neumega Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Genetics Institute, Inc Sep 18 2002
oprelvekin Neumega warnings regarding ophthalmologic and ventricular arrhythmias adverse events have been added to the oprelvekin (Neumega) label Wyeth Sep 13 2006
oxaliplatin Eloxatin Accel. Approv. (clinical benefit not established) in combination with infusional 5-FU/LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan. Sanofi Synthelabo Aug 09 2002
oxaliplatin Eloxatin Conversion to regular approval for use in combination with infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) for the treatment of patients previously untreated for advanced colorectal cancer Sanofi Synthelabo Jan 09 2004
oxaliplatin Eloxatin for use in combination with infusional 5-FU/LV, for the adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor Sanofi Synthelabo Nov 04 2004
paclitaxel Abraxane for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Abraxis Feb 15 2007
paclitaxel Paxene treatment of advanced AIDS-related Kaposi’s sarcoma after failure of first line or subsequent systemic chemotherapy Baker Norton Pharmaceuticals, Inc Dec 24 1997
paclitaxel Taxol Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. Bristol-Myers Squibb Dec 29 1992
paclitaxel Taxol Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Bristol-Myers Squibb Apr 13 1994
paclitaxel Taxol New dosing regimen for patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary Bristol-Myers Squibb Jun 22 1994
paclitaxel Taxol second line therapy for AIDS related Kaposi’s sarcoma. Bristol-Myers Squibb Aug 04 1997
paclitaxel Taxol For first-line therapy for the treatment of advanced carcinoma of the ovary in combination with cisplatin. Bristol-Myers Squibb Apr 09 1998
paclitaxel Taxol for use in combination with cisplatin, for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Bristol-Myers Squibb Jun 30 1998
paclitaxel Taxol For the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination therapy. Bristol-Myers Squibb Oct 25 1999
paclitaxel Taxol First line ovarian cancer with 3 hour infusion. Bristol-Myers Squibb Jun 20 2000
paclitaxel protein-bound particles Abraxane For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracyline unless clinically contraindicated AM Bioscience Jan 07 2005
palifermin Kepivance Decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoetic stem cell support Amgen Dec 15 2004
pamidronate Aredia Treatment of osteolytic bone metastases of breast cancer in conjunction with standard antineoplastic therapy. Novartis Sep 22 1998
panitumumab Vectibix to treat metastatic colorectal carcinoma Amgen Sep 27 2006
pegademase Adagen (Pegademase Bovine) Enzyme replacement therapy for patients with severe combined immunodeficiency asa result of adenosine deaminase deficiency. Enzon Mar 21 1990
pegaspargase Oncaspar Acute lymphoblastic leukemia Enzon Jul 24 2006
pegaspargase Oncaspar Acute lymphocytic leukemia in L-asparaginase hypersensitive patients Enzon, Inc Feb 01 1994
Pegfilgrastim Neulasta Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Amgen, Inc Jan 31 2002
Peginterferon alfa-2b PegIntron trade name from PEG-Intron to PegIntron Schering Dec 22 2006
pemetrexed disodium Alimta For use in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery Lilly Feb 04 2004
pemetrexed disodium Alimta Accel. Approv. (clinical benefit not established) as a single agent for the treatment of patients with locally advanced or metastatic non-small lung cancer after prior chemotherapy Lilly Aug 19 2004
pentostatin Nipent Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia. Parke-Davis Pharmaceutical Co. Oct 11 1991
pentostatin Nipent Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.) Parke-Davis Pharmaceutical Co. Sep 29 1993
pipobroman Vercyte Abbott Labs Jul 01 1966
plicamycin, mithramycin Mithracin Pfizer Labs May 05 1970
porfimer sodium Photofrin For the ablation of high-grade dysplasia in Barrett’s esophagus patients who do not undergo esophagectomy Axcan Scandipharm Aug 01 2003
porfimer sodium Photofrin For use in photodynamic therapy (PDT) for palliation of patients with completely obstructing esophageal cancer, or patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with ND-YAG laser therapy. QLT Phototherapeutics Inc. Dec 27 1995
porfimer sodium Photofrin For use in photodynamic therapy for treatment of microinvasive endobronchial nonsmall cell lung cancer in patients for whom surgery and radiotherapy are not indicated. QLT Phototherapeutics Inc. Jan 09 1998
porfimer sodium Photofrin For use in photodynamic therapy (PDT) for reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobroncial nonsmall cell lung cancer (NSCLC). QLT Phototherapeutics Inc. Dec 22 1998
procarbazine Matulane Sigma Tau Pharms Jul 22 1969
quinacrine Atabrine Abbott Labs Dec 07 1964
Rasburicase Elitek ELITEK is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Sanofi-Synthelabo, Inc Jul 12 2002
rituximab Rituxan for the first-line treatment of patients with low grade or follicular, CD20-positive B-cell non-Hodgkin’s lymphoma. Genentech Sep 29 2006
rituximab Rituxan for the first-line treatment of patients with low grade or follicular, CD20-positive B-cell non-Hodgkin’s lymphoma. Genentech Sep 29 2006
Rituximab Rituxan Treatment of patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma Genentech, Inc Nov 26 1997
Rituximab Rituxan non-Hodgkin’s lymphoma Genentech, Inc Feb 10 2006
sargramostim Leukine Acceleration of myeloid recovery following autologous bone marrow transplant in patients with non-Hodgkin’s lymphoma, acute lymphocytic leukemia, or Hodgkin’s disease Berlex Mar 05 1991
Sargramostim Prokine Immunex Corp Nov 07 1996
sorafenib Nexavar For the treatment of patients with advanced renal cell carcinoma Bayer Dec 20 2005
streptozocin Zanosar Antineoplastic agent. Pharmacia & Upjohn Company May 07 1982
sunitinib Sutent for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; for the treatment of advanced renal cell carcinoma. CP Pharmaceuticals Feb 02 2007
sunitinib maleate Sutent treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate Pfizer Jan 26 2006
sunitinib maleate Sutent Accel. Approv. (clinical benefit not established) for the treatment of advanced renal cell carcinoma. Approval for advanced renal cell carcinoma is based on partial response rates and duration of responses. There are no randomized trials of SUTENT demonstrating clinical benefit such as increased survival or improvement in disease-related symptoms in renal cell carcinoma. Pfizer Jan 26 2006
talc Sclerosol For the prevention of the recurrence of malignant pleural effusion in symptomatic patients. Bryan Dec 24 1997
tamoxifen Nolvadex AstraZeneca Pharmaceuticals Dec 30 1977
tamoxifen Nolvadex As a single agent to delay breast cancer recurrence following total mastectomy and axillary dissection in postmenopausal women with breast cancer (T1-3, N1, M0) AstraZeneca Pharmaceuticals Dec 03 1986
tamoxifen Nolvadex For use in premenopausal women with metastatic breast cancer as an alternative to oophorectomy or ovarian irradiation AstraZeneca Pharmaceuticals Mar 16 1989
tamoxifen Nolvadex For use in women with axillary node-negative breast cancer adjuvant therapy. AstraZeneca Pharmaceuticals Jun 21 1990
tamoxifen Nolvadex Metastatic breast cancer in men. AstraZeneca Pharmaceuticals Apr 01 1993
tamoxifen Nolvadex Equal bioavailability of a 20 mg Nolvadex tablet taken once a day to a 10 mg Nolvadex tablet taken twice a day. AstraZeneca Pharmaceuticals Mar 21 1994
tamoxifen Nolvadex to reduce the incidence of breast cancer in women at high risk for breast cancer AstraZeneca Pharmaceuticals Oct 29 1998
tamoxifen Nolvadex In women with DCIS, following breast surgery and radiation, Nolvadex is indicated to reduce the risk of invasive breast cancer. AstraZeneca Pharmaceuticals Jun 29 2000
temozolomide Temodar Accel. Approv. (clinical benefit not established) Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse with disease progression on a nitrosourea and procarbazine containing regimen Schering Aug 11 1999
temozolomide Temodar Conversion to regular approval for the treatment of patients with newly diagnosed high grade gliomas concomitantly with radiotherapy and then as adjuvant treatment Schering Mar 15 2005
teniposide, VM-26 Vumon In combination with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all). Bristol-Myers Squibb Jul 14 1992
testolactone Teslac Bristol-Myers Squibb Jun 03 1969
testolactone Teslac Bristol-Myers Squibb May 27 1970
thalidomide Thalomid Multiple myeloma Celgene May 26 2006
thioguanine, 6-TG Thioguanine GlaxoSmithKline Jan 18 1966
thiotepa Thioplex Immunex Corporation Mar 09 1959
thiotepa Thioplex Immunex Corporation Dec 22 1994
thiotepa Thioplex Lederle Laboratories Aug 15 1990
topotecan Hycamtin Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. GlaxoSmithKline May 28 1996
topotecan Hycamtin Treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy GlaxoSmithKline Nov 30 1998
topotecan hcl Hycamtin Cervical carcinoma GlaxoSmithKline Jun 14 2006
toremifene Fareston Treatment of advanced breast cancer in postmenopausal women. Orion Corp. May 29 1997
Tositumomab Bexxar Accel. Approv. (clinical benefit not established) Treatment of patients with CD20 positive, follicular, non-Hodgkin’s lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy Corixa Corporation Jun 27 2003
Tositumomab/I-131 tositumomab Bexxar Expand the indication to include patients with relapsed or refractory low grade follicular transformed CD20-positive non-Hodgkin’s lymphoma who have not received rituximab GlaxoSmithKline Dec 22 2004
trastuzumab Herceptin Early Stage Breast Cancer After Primary Therapy Genentech Nov 16 2006
Trastuzumab Herceptin HERCEPTIN as a single agent is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. Genentech, Inc Sep 25 1998
Trastuzumab Herceptin Herceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 protein and had not received chemotherapy for their metastatic disease Genentech, Inc Feb 09 2000
Trastuzumab Herceptin Genentech, Inc Aug 28 2002
Trastuzumab Herceptin Genentech, Inc Aug 28 2002
tretinoin, ATRA Vesanoid Induction of remission in patients with acute promyelocytic leukemia (APL) who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens. Roche Nov 22 1995
Uracil Mustard Uracil Mustard Capsules Roberts Labs Sep 13 1962
valrubicin Valstar For intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Anthra –> Medeva Sep 25 1998
vinblastine Velban Eli Lilly Nov 05 1965
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vincristine Oncovin Eli Lilly Jul 10 1963
vinorelbine Navelbine Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). GlaxoSmithKline Dec 23 1994
vinorelbine Navelbine Navelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unreseactable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Navelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Navelbine is indicated in combination with cisplatin. GlaxoSmithKline Nov 05 2002
vorinostat Zolinza for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Merck Oct 06 2006
zoledronate Zometa the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Novartis Feb 22 2002
zoledronic acid Zometa Treatment of hypercalcemia of malignancy Novartis Aug 20 2001

Related Posts

Post a Comment